One major medical watchdog has just approved a 'triple-strength' weight loss jab that could give people who are struggling with current options an alternative amid growing GLP-1 usage across the world.
GLP-1 injections like Ozempic and Mounjaro might have initially been intended for use in people with diabetes, but the jabs have proven to be a transformative option for losing weight.
It was discovered a few years ago that anyone could be prescribed these drugs as a means of shedding the pounds quickly, as gruesome simulations have shown how it affects your hunger and slows down your digestion, causing you to eat less.
While there are a number of concerning (and often bizarre) side effects that come with taking these drugs, they've provided a clear benefit for individuals who are overweight or obese, with statistics painting a clear picture since they became widespread.
Advert
For some, however, the current dosage levels aren't enough to achieve their desired results and they've been left wondering what options they have going forward.
That's where one new 'triple-strength' version of these drugs could come in handy, as it has just been approved by the NHS watchdog for use in the United Kingdom, as long as you meet the specific conditions.
As shared by LADbible, this new form triples the current dosage limit of 2.4mg, offering certain patients a once-a-week 7.2mg dose of semaglutide, which will then be delivered in three separate dosages.
This won't be available to everyone though, as only those who have a BMI of 30 or higher will qualify for this new and enhanced form — and doctors will likely also make them aware of the enhanced side effects that will likely come with the increased dosage.
The STEP UP clinical trial that saw this triple-strength dosage approved showed that participants were able to achieve a 20.7 percent weight loss while taking the 7.2mg version, with an increase loss of 25 percent or more to their overall body weight over 72 weeks compared to the standard dosage.
It's not available just yet though, as it still needs to pass a review from the National Institute for Health and Care Excellence (NICE) before doctors can prescribe it to their patients, although it likely won't be too long if it's successful in this regard.
Sebnem Avsar Tuna, general manager at Ozempic creator Novo Nordisk's UK division, outlined that "this approval represents another important step in Novo Nordisk supporting people living with obesity to achieve meaningful and significant weight loss."